Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. infection leading
Show results for
Products
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Infection Leading Articles & Analysis

38 news found

China risks between 1.3 and 2.1 million deaths if it ends its zero-COVID strategy

China risks between 1.3 and 2.1 million deaths if it ends its zero-COVID strategy

Analysis by Airfinity shows between 1.3 and 2.1 million lives could be at risk if China lifts its zero-COVID policy given low vaccination and booster rates as well as a lack of hybrid immunity. Airfinity’s risk analysis uses cumulative peak cases and deaths from Hong Kong's BA.1 wave as a proxy for mainland China. Hong Kong took a zero-COVID approach for the first two years of the ...

ByAirfinity Limited


World Sepsis Day – Raising awareness about one of the most prevalent and deadly, yet misdiagnosed, medical conditions.

World Sepsis Day – Raising awareness about one of the most prevalent and deadly, yet misdiagnosed, medical conditions.

Sepsis is the body’s over active and toxic response to an infection that causes hospitalization of more than 18 million people around the world every year, including 30,000 Canadians Declared a Global Health Priority by the World Health Organization in 2017 80% of sepsis deaths in hospitals could be prevented with rapid diagnosis and treatment Vancouver, Canada: ...

BySepset Biosciences Inc.


Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri

About Hepatitis B Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. ...

ByVBI Vaccines Inc.


Ondine reports successful US Phase 2 trial data

Ondine reports successful US Phase 2 trial data

aureus is the primary pathogen associated with surgical site infections (SSIs).[i] No reportable adverse events. Ondine Biomedical Inc. ...

ByOndine Biomedical Inc


VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer

Dillman was also responsible for all segment, consumer, and digital marketing activities, and spent three years as the General Manager of VaxServe, a Sanofi Pasteur company and a leading specialty distributor of vaccines. About Hepatitis B Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people ...

ByVBI Vaccines Inc.


VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022

About Hepatitis B Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. ...

ByVBI Vaccines Inc.


VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri, a 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri, a 3-Antigen Adult Hepatitis B Vaccine

(Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] for active immunisation against infection caused by all ...

ByVBI Vaccines Inc.


VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022

VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022

Oral Presentation Details Abstract Number: 1416 Title: Long term persistence of Anti-HBs antibodies after vaccination with a 3-antigen HBV vaccine compared to a single-antigen HBV vaccine Session: Viral hepatitis B/D: Clinical aspects except therapy Date: Sunday, June 26, 2022 Time: 10:00-11:30 AM BST Presenter: Timo Vesikari, M.D., Ph.D., Professor Emeritus and Director of the Nordic ...

ByVBI Vaccines Inc.


CloudCath Announces $12 Million Series A Financing for Technology Enabling Remote, Real-Time Complication Monitoring for At-Home Dialysis

CloudCath Announces $12 Million Series A Financing for Technology Enabling Remote, Real-Time Complication Monitoring for At-Home Dialysis

For patients undergoing peritoneal dialysis (PD), rates of infection-driven hospitalization are as high as 0.5 hospitalizations per patient year, according to the U.S. ...

ByCloudCath


Dynavax Highlights 2022 Priorities and Announces Initiation of Phase 1 Clinical Trial for Its Shingles Vaccine Candidate

Dynavax Highlights 2022 Priorities and Announces Initiation of Phase 1 Clinical Trial for Its Shingles Vaccine Candidate

CpG 1018 Adjuvanted Shingles (Herpes Zoster) Vaccine Candidate Enters the Clinic Shingles is an extremely painful consequence of the reactivation of a latent varicella zoster virus infection, with attacks leading to potential complications including chronic pain. ...

ByDynavax Technologies Corporation


Nob Hill Therapeutics Announces Strategic Advisory Board to Accelerate Growth

Nob Hill Therapeutics Announces Strategic Advisory Board to Accelerate Growth

She has a specialist interest in complex lung infection and is the clinical lead for the South Manchester Bronchiectasis Service. ...

ByNob Hill Therapeutics


NIAID awards Phase I contract to Kephera Diagnostics for the development of a new test for Chagas disease

NIAID awards Phase I contract to Kephera Diagnostics for the development of a new test for Chagas disease

It is the most prevalent parasitic disease in the western hemisphere, infecting 6-7 million people with over 70 million at risk. Moreover, CDC estimates approximately 300,000 cases in the U.S., principally among individuals who acquired it in endemic countries, although some autochthonous infections have also been reported. Chagas can also be transmitted ...

ByKephera Diagnostics, LLC


Nob Hill Therapeutics Selected as a Finalist for RESI Innovator’s Pitch Challenge

Nob Hill Therapeutics Selected as a Finalist for RESI Innovator’s Pitch Challenge

NHT focuses on creating effective inhalation therapies to address lower respiratory tract infections (the 5th leading overall cause of death worldwide) and other deadly lung diseases. ...

ByNob Hill Therapeutics


U.S. Nationwide Commercial Availability of the VenSure Balloon Sinus Dilation System and Cube Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

U.S. Nationwide Commercial Availability of the VenSure Balloon Sinus Dilation System and Cube Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

Over time, the sinuses can become infected leading to inflammation and pain. Up to 60% of CRS patients may not experience significant improvements in their symptoms despite trying multiple over the counter and prescription medications. ...

ByIntersect ENT, Inc.


Accelerate Diagnostics Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections

Accelerate Diagnostics Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections

Sepsis is the body’s overwhelming and life-threatening response to an infection that can lead to tissue damage, organ failure and death. Speed is critical in diagnosing infections and sepsis. ...

ByAccelerate Diagnostics, Inc.


PhotoniCare Announces Rebranding of First-in-Class Technology for Imaging the Middle Ear, Now called OtoSight Middle Ear Scope

PhotoniCare Announces Rebranding of First-in-Class Technology for Imaging the Middle Ear, Now called OtoSight Middle Ear Scope

[i] “Current tools can only provide a view of the surface of the eardrum, forcing healthcare providers to make an assessment with very limited information, or to employ invasive surgical procedures to accurately identify middle ear pathologies,” said Diego Preciado, M.D., Ph.D. of the Children’s National Hospital in Washington, D.C., a lead investigator for ...

ByPhotoniCare Inc.


Fibralign Announces Start of European Lymphedema Prevention Clinical Study

Fibralign Announces Start of European Lymphedema Prevention Clinical Study

Such interventions, while lifesaving, can also destroy enough lymphatic function that the cancer survivor is left with a condition in the affected limb that includes painful swelling and frequent infections. Lymphedema can ultimately lead to irreversible structural changes in the tissues, which can result in severe deformity, serious reduction in function and ...

ByFibralign Corporation


Fibralign Announces CE Mark Approval for BioBridge

Fibralign Announces CE Mark Approval for BioBridge

Such interventions, while life-saving, can also destroy enough lymphatic function that the cancer survivor is left with a condition in the affected limb that includes painful swelling and frequent infections. Lymphedema can ultimately lead to irreversible structural changes in the tissues, which can result in severe deformity, serious reduction in function and ...

ByFibralign Corporation


20th Annual Biotech in Europe Forum for global partnering & investments

20th Annual Biotech in Europe Forum for global partnering & investments

The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications: ApyraVax with the lead indication of Clostridioides difficile infection ApyraMed with lead indications as immune modulator ...

ByMV BioTherapeutics SA


Bio International Convention Digital June 8-12, 2020

Bio International Convention Digital June 8-12, 2020

The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications: ApyraVax with the lead indication of Clostridioides difficile infection ApyraMed with lead indications as immune modulator ...

ByMV BioTherapeutics SA

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT